NCT00735449

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 204 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%	1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
DRUG	timolol maleate 0.5%	1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
DRUG	latanoprost 0.005%	1 drop of latanoprost 0.005% once nightly.

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2008-08-15
• Last updated: 2019-04-23
• Results posted: 2011-11-24

Locations

2 sites across 2 countries: United States, Canada